Sun Pharma Q1 FY27: Sales up 10%, PAT jumps 27%, Organon on track
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty 100 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sun Pharma reported Q1FY27 consolidated sales at Rs 151,836 million, up 10.1% YoY. Reported PAT jumped to Rs 28,948 million from Rs 22,786 million, about 27% growth. EBITDA rose 2.7% to Rs 44,177 million but margin fell to 28.9% from 31.1%. India formulations grew 16% to Rs 54,749 million; US sales dropped 9.7% to USD 427 million. Results include a Rs 2,040 million exceptional charge for Organon acquisition costs and labour code adjustments.
Strong PAT growth despite US weakness and margin pressure. Organon acquisition of USD 11.75 bn on track to close early 2027. Net cash at USD 3.4 bn.